The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
iPSC Phenotyping Environmental Exposure Program, 2024Establishing a Proof-of-concept, Automated Platform for Studying the Interactions of Genetic and Environment-based Toxicity in Human Cell Models of Parkinson’s Disease
Study Rationale: Many studies of Parkinson’s disease (PD) focus on investigating the disease’s genetic component. Yet only about 22% of PD diagnoses carry a genetic association. Increasing evidence...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Validating Hallmarks of Inflammation in a Preclinical Alpha-synuclein Model of Parkinson’s Disease
Study Rationale: Inflammation and abnormal protein clumps in the brain are strongly associated with Parkinson's disease (PD). To study the mechanism of inflammation and disease progression related to...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025(SUPPLEMENT) Discovery of Translational Biomarkers for Endolysosomal Pathway Pathology Using Lipidomics and Metabolomics
Study Rationale: The endolysosomal system in living cells is comprised of small, specialized structures that contain enzymes that degrade proteins and remove molecular waste. Impaired function of this...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025GBA1 Consortium: Joint Analysis to Inform Clinical Trials
Study Rationale: Variants in the GB1A gene represent the most important genetic risk factor for Parkinson’s disease (PD) across the globe. However, different GBA1 variants are associated with varied...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Development of Alpha-synuclein Seed Amplification Assay in Cerebrospinal Fluid as a Robust Biomarker of Synucleinopathies
Study Rationale: Progressive aggregation of alpha-synuclein and the subsequent loss of affected brain cells starts 10 to 20 years before the onset of Parkinson’s disease (PD) symptoms. Early diagnosis...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Investigating the Early Events in Parkinson’s Disease Pathobiology through Longitudinal Evaluation of Asymptomatic Carriers of Alpha-synuclein Mutations
Study Rationale: Essentially nothing is known about the sequence of biological and physiological events that ultimately lead to the clinical manifestations of Parkinson’s disease (PD). The existence...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.